TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
The following is a summary of the four presentations that will be given at
Poster Discussion Presentations | |
Title: | A Phase I Trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients |
with solid tumors and lymphomas (Abstract #2518) | |
Presenter: | Robert S. Meehan, MD, National Cancer Institute |
Location: | S Hall A, Poster Board 10 (poster display) |
Arie Crown Theater (poster discussion) | |
Date/Time: | Monday, June 5, 2017, 8:00 AM – 11:30 AM, Central time (poster display) |
Monday, June 5, 2017, 11:30 AM – 12:45 PM, Central time (poster discussion) | |
Title: | NCCTG N1174: Phase I/comparative randomized Phase II trial of TRC105 plus |
bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Abstract #2023) | |
Presenter: | Evanthia Galanis, MD, Mayo Clinic |
Location: | S Hall A, Poster Board 265 (poster display) |
S404 (poster discussion) | |
Date/Time: | Monday, June 5, 2017, 1:15 PM – 4:45 PM, Central time (poster display) |
Monday, June 5, 2017, 4:45 PM – 6:00 PM, Central time (poster discussion) | |
General Poster Presentations | |
Title: | Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF |
therapy (Abstract #11546) | |
Presenter: | Yingmiao Liu, Ph.D., Duke University Medical Center |
Location: | S Hall A, Poster Board 246 |
Date/Time: | Saturday, June 3, 2017, 1:15 PM – 4:45 PM, Central time |
Title: | TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus |
pazopanib alone in patients with advanced angiosarcoma (Abstract #TPS11081) | |
Presenter: | Robin Lewis Jones, BSc, MB, MRCP, MD, Royal Marsden Hospital |
Location: | S Hall A, Poster Board 403a |
Date/Time: | Sunday, June 4, 2017, 8:00 AM – 11:30 AM, Central time |
About Carotuximab (TRC105)
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the
About TRC102
TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Company Contact:Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact:Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com